Portal de Periódicos da CAPES

Comparison of the immunogenicity of five COVID‐19 vaccines in Sri Lanka

2022; Wiley; Volume: 167; Issue: 2 Linguagem: Inglês

10.1111/imm.13535

1365-2567

Chandima Jeewandara, Inoka Sepali Aberathna, Saubhagya Danasekara, Laksiri Gomes, Suranga Fernando, Dinuka Guruge, Thushali Ranasinghe, Banuri Gunasekera, Achala Kamaladasa, Heshan Kuruppu, Gayasha Somathilake, Jeewantha Jayamali, Deshni Jayathilaka, Helanka Dinesh Kumara Wijayatilake, Pradeep Darshana Pushpakumara, Michael Harvie, Thashmi Nimasha, Shiromi Devika Grace de Silva, Ruwan Wijayamuni, Lisa Schimanski, Pramila Rijal, Jack Tan, Alain Townsend, Graham S. Ogg, Gathsaurie Neelika Malavige,

vaccines and immunoinformatics approaches

Abstract To determine the antibody responses elicited by different vaccines against SARS‐CoV‐2, we compared antibody responses in individuals 3 months post‐vaccination in those who had received different vaccines in Sri Lanka. Abs to the receptor binding domain (RBD) of the ancestral (wild type) virus (WT) as well as to variants of concern (VoCs), and ACE2 blocking Abs, were assessed in individuals vaccinated with Moderna ( n = 225), Sputnik V ( n = 128) or Sputnik light ( n = 184) and the results were compared with previously reported data on Sinopharm and AZD1222 vaccinees. A total of 99.5% of Moderna, >94% of AZD1222 or Sputnik V and >70% of Sputnik light, >60% of Sinopharm vaccine recipients, had a positive response to ACE2 blocking antibodies. The ACE2 blocking antibody levels were highest to lowest was Moderna > Sputnik V/AZD1222 (had equal levels) > Sputnik light > Sinopharm. All Moderna recipients had antibodies to the RBD of WT, alpha and beta, while positivity rates for delta variant was 80%. The positivity rates for Sputnik V vaccinees for the WT and VoCs were higher than for AZD1222 vaccinees while those who received Sinopharm had the lowest positivity rates (<16.7%). The total antibodies to the RBD were highest for the Sputnik V and AZD1222 vaccinees. The Moderna vaccine elicited the highest ACE2 blocking antibody levels followed by Sputnik V/AZD1222, while those who received Sinopharm had the lowest levels. These findings highlight the need for further studies to understand the effects on clinical outcomes.